A
Andrew G. Nicholson
Researcher at National Institutes of Health
Publications - 512
Citations - 87875
Andrew G. Nicholson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 113, co-authored 477 publications receiving 73860 citations. Previous affiliations of Andrew G. Nicholson include National Yang-Ming University & University College London.
Papers
More filters
Journal Article
BRAF and RAS mutations in human lung cancer and melanoma
Marcia S. Brose,Patricia Volpe,Michael Feldman,Madhu S. Kumar,Irum Rishi,Renee M. Gerrero,Eugene Einhorn,Meenhard Herlyn,John D. Minna,Andrew G. Nicholson,Jack A. Roth,Steven M. Albelda,Helen Davies,Charles Cox,Graham Brignell,Philip J. Stephens,P. Andrew Futreal,Richard Wooster,Michael R. Stratton,Barbara L. Weber +19 more
TL;DR: Three BRAF mutations identified in this study are novel, altering residues important in AKT-mediated BRAF phosphorylation and suggesting that disruption ofAKT-induced BRAF inhibition can play a role in malignant transformation, first report of mutations documenting this interaction in human cancers.
Journal ArticleDOI
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.
TL;DR: The 2015 WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart features the incorporation of many exciting new advances in thoracic tumor diagnosis and classification.
Journal ArticleDOI
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Harold R. Collard,Bethany B. Moore,Kevin R. Flaherty,Kevin K. Brown,Robert J. Kaner,Talmadge E. King,Joseph A. Lasky,James E. Loyd,Imre Noth,Mitchell A. Olman,Ganesh Raghu,Jesse Roman,Jay H. Ryu,David A. Zisman,Gary W. Hunninghake,Thomas V. Colby,Jim J. Egan,David M. Hansell,Takeshi Johkoh,Naftali Kaminski,Dong Soon Kim,Yasuhiro Kondoh,David A. Lynch,Joachim Müller-Quernheim,Jeffrey L. Myers,Andrew G. Nicholson,Moisés Selman,Galen B. Toews,Athol U. Wells,Fernando J. Martinez +29 more
TL;DR: An international effort to summarize the current state of knowledge regarding acute exacerbations of IPF is presented, and proposed diagnostic criteria include subjective worsening over 30 days or less, new bilateral radiographic opacities, and the absence of infection or another identifiable etiology.
Journal ArticleDOI
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi,Ulrich Costabel,Moisés Selman,Dong Soon Kim,David M. Hansell,Andrew G. Nicholson,Kevin K. Brown,Kevin R. Flaherty,Paul W. Noble,Ganesh Raghu,Michèle Brun,Abhya Gupta,Nolwenn Juhel,Matthias Klüglich,Roland M. du Bois +14 more
TL;DR: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life.
Journal ArticleDOI
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Maurits Demedts,Juergen Behr,Roland Buhl,Ulrich Costabel,Richard Dekhuijzen,Henk M. Jansen,William MacNee,Michiel Thomeer,Benoit Wallaert,François Laurent,Andrew G. Nicholson,Eric Verbeken,Johny Verschakelen,Christopher D.R. Flower,Frédérique Capron,Stefano Petruzzelli,Paul De Vuyst,Jules M.M. van den Bosch,Eulogio Rodriguez-Becerra,Giuseppina Corvasce,Ida Lankhorst,Marco Sardina,Mauro Montanari +22 more
TL;DR: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.